Clinical Trial

Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol

Study acronym: PPP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out. The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory. Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-07-21.
Status change: Not Yet Recruiting → Recruiting 2023-08-25
Trial Details
NCT Number NCT04985344
Lead Sponsor University Hospital, Toulouse
Conditions PTSD
Enrollment 92 participants
Start Date 2023-02-01
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2023-08-28